Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Pharma
Enspryng falls short of Roche's expectations in myasthenia gravis
Roche’s labeling Enspryng’s data as weak was a relief for other developers of biologics for gMG, such as Johnson & Johnson, UCB and argenx.
Angus Liu
Mar 21, 2024 11:28am
Lonza strikes $1.2B deal to buy mammoth Roche plant
Mar 20, 2024 11:33am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm
FDA approves Roche, Novartis' Xolair for common food allergies
Feb 16, 2024 2:28pm
Leqembi, Takeda, Roche—Fierce Pharma Asia
Feb 9, 2024 9:02am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am